Glycemic Load, Metabolism & Obesity in Pregnancy (PANS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01287299|
Recruitment Status : Completed
First Posted : February 1, 2011
Last Update Posted : February 1, 2011
|Condition or disease||Intervention/treatment|
|Obesity Insulin Resistance||Other: Low Glycemic Load diet Other: Low Fat Diet|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dietary Glycemic Load & Metabolism in Obese Pregnant Women|
|Study Start Date :||July 2005|
|Primary Completion Date :||December 2009|
|Study Completion Date :||December 2009|
Experimental: Low Glycemic Load Diet
Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.
Other: Low Glycemic Load diet
Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
Other Name: LGL Diet
Experimental: Low Fat Diet
Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.
Other: Low Fat Diet
Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
Other Name: LF Diet
- maternal body fat gain [ Time Frame: 20-34 weeks gestation ]Changes in total body fat as measured by air displacement between 20 to 34 weeks gestation
- Insulin Resistance [ Time Frame: 20-34 weeks gestation ]Changes in insulin resistance measured during an oral glucose tolerance test between 20 to 34 weeks gestation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01287299
|United States, California|
|San Francisco General Hospital|
|San Francisco, California, United States, 94110|